Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease

Fig. 3

Freedom from target lesion revascularization (A), bypass conversion (B), major amputation (C), major adverse limb events (D), all-cause death (E), and cardiovascular death (F) in the propensity score-matched population. Dotted lines indicate 95% confidence intervals. SE, standard error; SGLT2, sodium-glucose co-transporter 2

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840